1449429-88-2

Basic information

• Product Name: C₁₈H₂₀FN₃O₃
• CAS NO: 1449429-88-2
• Molecular Weight: 345.374
• Mol File: 1449429-88-2.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: C₁₈H₂₀FN₃O₃(CAS DataBase Reference)
• NIST Chemistry Reference: C₁₈H₂₀FN₃O₃(1449429-88-2)
• EPA Substance Registry System: C₁₈H₂₀FN₃O₃(1449429-88-2)

Safety Data

• Hazardous Substances Data: 1449429-88-2(Hazardous Substances Data)

Upstream product

• 528587-70-4 (1S,5R)-2-oxo-1-(3-fluorophenyl)-3-oxabicyclo[3.1.0]hexane 
• 1369767-20-3 ((1S,2R)-1-(3-fluorophenyl)cyclopropane-1,2-diyl)dimethanol 
• 1369768-29-5 [(1R,2S)-2-(3-fluorophenyl)-2-(hydroxymethyl)cyclopropyl]-methyl acetate 
• 1369768-06-8 C₁₈H₁₉FN₂O₄ 
• 501-00-8 3-fluorophenylacetonitrile 

Downstream Products

• 1369764-98-6 (1R,2S)-2-(((2-methyl-4-methoxymethylpyrimidin-5-yl)oxy)methyl)-N-(5-fluoropyridin-2-yl)-2-(3-fluorophenyl)cyclopropanecarboxamide 

Relevant articles and documents

Synthesis and evaluation of novel radioligands for positron emission tomography imaging of the orexin-2 receptor

Orexin receptors (OXRs) in the brain have been implicated in diverse physiological and neuropsychiatric conditions. Here we describe the design, synthesis, and evaluation of OXR ligands related to (1R,2S)-2-(((2-methyl-4- methoxymethylpyrimidin-5-yl)oxy)methyl)-N-(5-fluoropyridin-2-yl) -2-(3-fluorophenyl)cyclopropanecarboxamide (9a) applicable to positron emission tomography (PET) imaging. Structural features were incorporated to increase binding affinity for OXRs, to enable carbon-11 radiolabeling, and to adjust lipophilicity considered optimal for brain penetration and low nonspecific binding. 9a displayed nanomolar affinity for OXRs, and autoradiography using rat brain sections showed that specific binding of [11C]9a was distributed primarily to neocortical layer VI and hypothalamus, consistent with reported localizations of orexin-2 receptors (OX2Rs). In vivo PET study of [11C]9a demonstrated moderate uptake of radioactivity into rat and monkey brains under deficiency or blockade of P-glycoprotein, and distribution of PET signals in the brain was in agreement with autoradiographic data. Our approach and findings have provided significant information for development of OX2R PET tracers.